Indinavir did not increase the short-term risk of adverse cardiovascular events relative to nucleoside reverse transcriptase inhibitor therapy in four phase III clinical trials.
AIDS
; 15(12): 1584-6, 2001 Aug 17.
Article
em En
| MEDLINE
| ID: mdl-11504995
ABSTRACT
A retrospective person-time analysis of the randomized and non-randomized extension phases of four phase III trials was performed to assess the incidence of adverse cardiovascular events in 2680 HIV-infected patients receiving indinavir or nucleoside reverse transcriptase inhibitor therapy, or both. The observed rate of cardiovascular events was not increased in patients receiving indinavir-based regimens compared with therapy without a protease inhibitor. Extrapolation of these findings is limited by the brief length of therapy and the small number of cases.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Doenças Cardiovasculares
/
Infecções por HIV
/
Inibidores da Transcriptase Reversa
/
Indinavir
/
Fármacos Anti-HIV
Tipo de estudo:
Etiology_studies
/
Observational_studies
/
Risk_factors_studies
Limite:
Humans
Idioma:
En
Ano de publicação:
2001
Tipo de documento:
Article